Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ethinylestradiol 30 µg (beige tablet); gestodene 50 µg (beige tablet); gestodene 70 µg (dark brown tablet); ethinylestradiol 40 µg (dark brown tablet); gestodene 100 µg (white tablet); ethinylestradiol 30 µg (white tablet) - coated tablet - ethinylestradiol 30 µg; gestodene 50 µg; gestodene 70 µg; ethinylestradiol 40 µg; gestodene 100 µg; ethinylestradiol 30 µg - progestogens and estrogens, fixed combinations

Malta - English - Medicines Authority

stragen uk limited castle court 41, london road, reigate, surrey, rh2prj, united kingdom - gestodene, ethinylestradiol - coated tablet - gestodene 75 µg ethinylestradiol 30 µg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

stragen uk limited castle court 41, london road, reigate, surrey, rh2prj, united kingdom - gestodene, ethinylestradiol - coated tablet - gestodene 75 µg ethinylestradiol 20 µg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

heaton k.s. na pankraci 14, 140 00 praha 4, czech republic - gestodene, ethinylestradiol - film-coated tablet - gestodene 0.06 mg ethinylestradiol 0.015 mg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet - excipient ingredients: maize starch; magnesium stearate; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

Malta - English - Medicines Authority

heaton k.s. na pankraci 14, 140 00 praha 4, czech republic - ethinylestradiol, gestodene - coated tablet - ethinylestradiol 0.020 mg gestodene 0.075 mg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

heaton k.s. na pankraci 14, 140 00 praha 4, czech republic - ethinylestradiol, gestodene - coated tablet - ethinylestradiol 0.03 mg gestodene 0.075 mg - sex hormones and modulators of the genital system